Clinical Trial

Transcriptomic Profiling of Cumulus Cells From CAPA-IVM

Recruiting

Record status

This record was last updated November 21, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-09-22; most recent amendment 2025-11-20.

Status change: Not Yet Recruiting → Recruiting 2025-11-20

Trial Details

NCT Number	NCT07197255
Lead Sponsor	Mỹ Đức Hospital Collaborators: Vrije Universiteit Brussel
Conditions	PCOS (Polycystic Ovary Syndrome), Cumulus Cell, Capacitation IVM, Transcriptomic Profiling
Enrollment	10 participants
Start Date	2025-10-16
Primary Completion	2026-01-30 (estimated)
Study Completion	2026-03-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-21